Merck gets $6.5bn after poor results as US blockbusters fly
Merck shrugged off concerns about its performance to lead more than $33bn of US high grade issuance this week, as the drugmaker became the latest big US company to finance a share buyback through the bond market.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: